Search results
Showing 1 to 9 of 9 results for goserelin
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]
In development [GID-TA11131] Expected publication date: TBC
Relugolix for treating hormone-sensitive prostate cancer [ID6187]
In development [GID-TA11141] Expected publication date: TBC
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced...
In development [GID-TA10261] Expected publication date: TBC
This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS91Show all sections
Sections for QS91
- Quality statements
- Quality statement 1: Discussion with a named nurse specialist
- Quality statement 2: Treatment options
- Quality statement 3: Combination therapy
- Quality statement 4: Managing adverse effects of treatment
- Quality statement 5: Hormone-relapsed metastatic prostate cancer
- Update information
- About this quality standard
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued [GID-TA10377]
luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced...